Abstract Library

#4078 Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,

#3203 The efficacy of above-label doses of long-acting somatostatin analogues for the management of patients with gastroenteropancreatic tumors

Introduction: Above-label doses of long-acting somatostatin analogues (SSAs) are increasingly used for the control of secretory syndrome or as anti-proliferative treatment in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Tsoli M, Daskalakis K, Koumarianou A, Kolomodi D, Anagnostou E,

Keywords: neuroendocrine tumor, somatostatin analogues, medical treatment,

#983 Vipomas: Report of Three Cases in Ten Years

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with an incidence of one in 10 million per year. Most cases arise within the pancreas, with others reported in the lungs, colon, liver, adrenals, and neuroganglia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Moletta L, Milanetto A, Liço V, De Carlo E, Alaggio R,

Keywords: vipoma, neuroendocrine tumors, pancreatic resections,

#836 Grade Increases In Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor

Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) has proved reliable for prognostic stratification of gastroenteropancreatic tumors (GEP). Although anecdotes have been published, no single study has evaluated whether grade changes between primary site and metastases.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Grillo F

Authors: Grillo F, Brisigotti M, Albertelli M, Borra T, Mastracci L,

Keywords: neuroendocrine, grade, Ki-67,

#189 Matrix metalloproteinases (MMPs) and Tissue Inhibitors of Matrix Metalloproteinases (TMIPs) in GEP NET Patients – A Potential Prognostic Biomarkers for Metastases

Introduction: MMPs have the ability to degrade the extracellular matrix and are responsible for tumor invasion and metastases. Higher TIMP-1 levels are associated with low survival rate in some types of cancer.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Blicharz-Dorniak J, Kos-Kudla B, Foltyn W, Zemczak A, Rosiek V,

Keywords: gastroenteropancreatic tumors, MMPs, TIMP1, metastases,